The increasing availability of prostate-specific membrane antigen positron emission tomography has been reported to offer superior detection of both primary and metastatic prostate cancer lesions compared to conventional CT and bone scintigraphy [9,10]. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.